After years of development and many published studies, prostate-specific membrane antigen–targeted radioligand therapy recently reached a critical milestone on March 23, 2022, with approval of 177Lu-PSMA-617 by the U.S. Food and Drug Administration ([ 1 ][1]). This landmark success heralds a new
No takes yet. Share an insight, caveat, or question.
Kuo et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: